Repository logo
 
Publication

Positron emitting tracers in pre-clinical drug development

2012Journal article Open access
Simple item page
dc.contributor.authorFernandes, E.
dc.contributor.authorBarbosa Moreira, Zélia
dc.contributor.authorClemente, G.
dc.contributor.authorAlves, F.
dc.contributor.authorJ. Abrunhosa, A.
dc.date.accessioned2022-12-29T12:52:18Z
dc.date.available2022-12-29T12:52:18Z
dc.date.issued2012
dc.description.abstractMolecular imaging tools such as Positron Emission Tomography (PET) are increasingly being used in the drug development process. The unrivaled sensitivity of PET coupled with a solid experience in developing highly targeted molecular probes makes this technique a very valuable tool at all stages from pre-clinical development to the clinical phases. Positron emitting tracers allow us to measure, quantitatively, molecular processes and interactions between a candidate drug and its molecular targets. This information can save time and money by directing development towards the most promising compounds and excluding molecules with unfavorable properties that would otherwise only be recognized as failures in latter stages of the process. In this paper we review the application of positron emitting tracers in the pre-clinical stages of the drug development process in the areas of oncology, cardiology, neurosciences and inflammatory diseases. PET tracers provide an important support for drug development in the areas of: discovery of new drug targets, clarification of pathophysiology, identification of potential drug candidates and validation of drug effectiveness, as well as the evaluation of pharmacokinetic and pharmacodynamic parameters in vivo.pt_PT
dc.description.versionN/Apt_PT
dc.identifier.doi10.2174/1874471011205020090pt_PT
dc.identifier.issn1874-4729
dc.identifier.urihttp://hdl.handle.net/10400.26/42900
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherBentham Science Publisherspt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/pt_PT
dc.subjectAnimal modelspt_PT
dc.subjectDrug developmentpt_PT
dc.subjectMolecular imagingpt_PT
dc.subjectRadiopharmaceuticalspt_PT
dc.subjectPositron emission tomographypt_PT
dc.subjectModelos animaispt_PT
dc.subjectDesenvolvimento de medicamentospt_PT
dc.subjectImagem molecularpt_PT
dc.subjectRadiofármacospt_PT
dc.subjectTomografia por emissão de pósitronspt_PT
dc.titlePositron emitting tracers in pre-clinical drug developmentpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage98pt_PT
oaire.citation.issue2pt_PT
oaire.citation.startPage90pt_PT
oaire.citation.titleCurrent Radiopharmaceuticalsept_PT
oaire.citation.volume5pt_PT
person.familyNameBarbosa Moreira
person.givenNameZélia
person.identifier.ciencia-id5213-E9A1-3FC5
person.identifier.orcid0000-0002-7527-1361
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication7edc1e73-ebd5-4f58-8574-38a40a4496f5
relation.isAuthorOfPublication.latestForDiscovery7edc1e73-ebd5-4f58-8574-38a40a4496f5

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Positron emitting tracers in pre-clinical drug development - abstract.pdf
Size:
372.58 KB
Format:
Adobe Portable Document Format
Download

Collections

IPC-ESTeSC - Artigos em revistas